Search

Anil Bhushan Phones & Addresses

  • Oakland, CA
  • San Francisco, CA
  • 806 Marco Pl, Venice, CA 90291 (310) 306-3408
  • 3907 Cumberland Ave, Los Angeles, CA 90027 (323) 660-4824
  • 3949 Cumberland Ave, Los Angeles, CA 90027 (323) 660-4824
  • 619 Levering Ave, Los Angeles, CA 90024
  • Chicago, IL
  • La Jolla, CA

Publications

Us Patents

Methods For The Regeneration Of Pancreatic Islets And Expansion Of Pancreatic Endocrine Cells

View page
US Patent:
20030138949, Jul 24, 2003
Filed:
Dec 10, 2002
Appl. No.:
10/315703
Inventors:
Anil Bhushan - Los Angeles CA, US
David Warburton - La Canada CA, US
International Classification:
A61K038/18
C12N005/08
US Classification:
435/366000, 514/012000
Abstract:
A method of facilitating the proliferation of pancreatic progenitor cells, particularly mammalian cells, is described. The method is carried out by administering an FGF polypeptide such as FGF-10 polypeptide to the cells in an amount effective to facilitate the proliferation thereof.

Inhibiting Senescent Processes In Beta Cells For The Prevention Of Type 1 Diabetes

View page
US Patent:
20200078376, Mar 12, 2020
Filed:
May 4, 2018
Appl. No.:
16/611158
Inventors:
- Oakland CA, US
Anil Bhushan - San Francisco CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/635
A61K 31/496
A61K 31/4025
A61K 31/5377
A61K 31/506
A61K 31/4412
A61K 31/427
A61K 31/4725
A61K 31/353
A61K 31/4545
A61K 31/12
A61K 31/45
A61K 31/5517
A61K 31/551
A61K 31/5415
A61K 31/55
A61K 31/517
A61K 31/437
A61K 31/519
A61K 31/541
A61K 31/145
A61K 31/41
A61P 3/10
Abstract:
The inventor of the present disclosure has advantageously elucidated the role of senescent processes in the development of Type 1 diabetes. Genotoxic stress responses, senescence, and acquisition of a SASP condition in beta cells are drivers that progress at-risk individuals to overt Type 1 diabetes. The administration of senolytic agents to at risk individuals selectively removes senescent cells and relieves beta cells from the factors which drive the development of overt Type 1 diabetes. Accordingly, Type 1 diabetes can be prevented in at-risk individuals by the administration of senolytic compositions. Additionally, given the major role of SASP in the development of Type 1 diabetes, the inhibition of SASP factors may be used to prevent Type 1 diabetes.
Anil Bhushan from Oakland, CA, age ~61 Get Report